Abbisko Cayman (STU:8ZD) Change In Receivables : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Abbisko Cayman Change In Receivables?

Abbisko Cayman's change in receivables for the quarter that ended in Dec. 2023 was €0.00 Mil. It means Abbisko Cayman's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

Abbisko Cayman's change in receivables for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Abbisko Cayman's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Abbisko Cayman's Accounts Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Abbisko Cayman's liquidation value for the six months ended in Dec. 2023 was €236.07 Mil.

Abbisko Cayman Change In Receivables Historical Data

The historical data trend for Abbisko Cayman's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Change In Receivables Chart

Abbisko Cayman Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Abbisko Cayman Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial			-	-	-	-	-

Abbisko Cayman Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Abbisko Cayman (STU:8ZD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Abbisko Cayman's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Abbisko Cayman's accounts receivable are only considered to be worth 75% of book value:

Abbisko Cayman's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	253.312	-	17.245	+	0.75 * 0	+	0.5 * 0
=	236.07

Abbisko Cayman Change In Receivables Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbisko Cayman (STU:8ZD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (STU:8ZD) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

02256:Hong Kong

Address

Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

https://www.abbisko.com

Abbisko Cayman Ltd is a investment holding company it operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.

Abbisko Cayman (STU:8ZD) Headlines

No Headlines